Mammographic density and exposure to air pollutants in premenopausal women: a cross-sectional study.

Background: Mammographic density (MD) is a well-established risk factor for breast cancer. Air pollution is a major public health concern and a recognized carcinogen. We aim to investigate the association between MD and exposure to specific air pollutants (SO, CO, NO, NO, NO, PM, PM, and O) in premenopausal females.

Breast Delineation in Full-Field Digital Mammography Using the Segment Anything Model.

Breast cancer is a major health concern worldwide. Mammography, a cost-effective and accurate tool, is crucial in combating this issue. However, low contrast, noise, and artifacts can limit the diagnostic capabilities of radiologists.

Residential exposure to traffic pollution and mammographic density in premenopausal women.

Background: Mammographic density (MD) is the most important breast cancer biomarker. Ambient pollution is a carcinogen, and its relationship with MD is unclear. This study aims to explore the association between exposure to traffic pollution and MD in premenopausal women.

Efficacy and safety of raltegravir plus lamivudine maintenance therapy.

Background: Decreasing medication burden with raltegravir plus lamivudine in virologically suppressed persons with HIV (PWH) maintained efficacy and was well tolerated at 24 weeks, but more comprehensive data over longer follow-up are required.

Methods: Prospective 48 week extension phase of the raltegravir plus lamivudine arm from a previous 24 week pilot randomized clinical trial in which virologically suppressed PWH were randomized 2:1 to switch to fixed-dose combination 150 mg lamivudine/300 mg raltegravir twice daily or to continue therapy. In this 48 week extension phase, raltegravir was dosed at 1200 mg/day and lamivudine 300 mg/day.

Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.

Background: While both the burden of therapy and the individual drugs in bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) and dolutegravir/lamivudine differ, it is unclear whether their real-life tolerability may be also different.

Methods: Single-centre, clinical cohort analysis of all virologically suppressed persons with HIV (PWH) who were first prescribed bictegravir as BIC/TAF/FTC or dolutegravir as dolutegravir/lamivudine and had taken ≥1 dose of study medication. Major outcomes were discontinuations either for any reason or due to toxicity.